In a short interview on RAC1 Radio, Lluís Ribas, ICREA researcher at IRB Barcelona, talks about the disturbing fall in the number of antibiotics available to treat infections—which has come about from “a vicious cycle between big pharma and regulatory agencies”. This decrease takes on great relevance given the increasing resistance of bacteria to antibiotics.
“Public-funded research can provide the solution, by allowing the constant discovery of new antibiotics to replace those to which bacteria have become resistant,” explains Lluís Ribas.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).